Setareh Seyedkazemi insider trades: Adverum Biotechnologies (ADVM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Setareh reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 15, 2025 | ADVM | ↓ Sell | 924 | $2.00 | $2K | Direct | May 16, 2025 (1d) |
| Sep 15, 2023 | ADVM | ↓ Sell | 6,201 | $1.52 | $9K | Direct | Sep 18, 2023 (3d) |
| Sep 19, 2022 | ADVM | ↓ Sell | 6,058 | $1.07 | $6K | Direct | Sep 21, 2022 (2d) |
| May 23, 2022 | ADVM | ↑ Buy | 20,000 | $0.84 | $17K | Direct | May 24, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ADVM insiders
Open-market trades in the last 12 months
About Setareh Seyedkazemi's insider trades
Setareh Seyedkazemi is Chief Development Officer at Adverum Biotechnologies (ADVM). Since May 23, 2022, Setareh has reported 1 open-market purchase worth $17K and 3 sales worth $18K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), shares returned to the company (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ADVM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.